



ABN 53 075 582 740

02 December 2021

ASX Market Announcements
ASX Limited
Level 4
Stock Exchange Centre
20 Bridge Street
SYDNEY NSW 2000

Dear Sir/Madam

RESULTS OF ANNUAL GENERAL MEETING

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution as set out in the attached proxy summary.

FOR FURTHER INFORMATION PLEASE CONTACT:

Ms Suzanne Irwin
Company Secretary
+61 8 8150 7400
CoSec@bionomics.com.au

About Bionomics Limited

Bionomics (ASX:BNO, OTCQB:BNOEF) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system ("CNS") disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral proprietary selective negative allosteric modulator of the $\alpha 7$ nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder ("SAD") and chronic treatment of Post-Traumatic Stress Disorder ("PTSD"). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions.

www.bionomics.com.au

BIONOMICS LIMITED
ANNUAL GENERAL MEETING - DECEMBER 2021
Thursday, 02 December 2021
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

| Resolution details | | Instructions given to validly appointed proxies (as at proxy close) | | | | Number of votes cast on the poll (where applicable) | | | Resolution Result |
|---|-----------------|--|--------------------|---------------------|-------------|--|---------------------|-------------|-----------------------|
| Resolution | Resolution Type | For | Against | Proxy's Discretion | Abstain | For | Against | Abstain* | Carried / Not Carried |
| 1 Adoption of Remuneration Report | Ordinary | 197,414,804 95.16% | 2,589,099 1.25% | 7,457,075 3.59% | 433,668 | 202,341,765 96.99% | 6,289,825 3.01% | 2,420,117 | Carried |
| 2 Election of Mr Peter Miles Davies as a Director | Ordinary | 198,700,080 94.86% | 1,920,539 0.92% | 8,838,099 4.22% | 280,019 | 206,994,514 97.36% | 5,621,265 2.64% | 280,019 | Carried |
| 3 Re-election of Mr David Wilson as a Director | Ordinary | 198,653,304 94.84% | 2,004,902 0.96% | 8,800,965 4.20% | 279,566 | 209,611,330 98.59% | 3,004,902 1.41% | 279,566 | Carried |
| 4 Approval of appointment of Auditor | Ordinary | 200,130,755 95.49% | 491,744 0.23% | 8,977,248 4.28% | 138,990 | 212,265,064 99.77% | 491,744 0.23% | 138,990 | Carried |
| 5 Adoption of the New Constitution | Special | 194,981,136 94.84% | 1,809,964 0.88% | 8,800,965 4.28% | 4,146,672 | 206,939,162 99.13% | 1,809,964 0.87% | 4,146,672 | Carried |
| 6 Ratification of prior issue of 110,287,131 Shares | Ordinary | 195,527,673 93.32% | 5,185,961 2.48% | 8,787,631 4.20% | 237,472 | 201,785,190 94.89% | 10,873,136 5.11% | 237,472 | Carried |
| 7 Ratification of prior issue of 21,137,380 Shares | Ordinary | 195,354,817 93.22% | 5,342,188 2.55% | 8,848,417 4.23% | 193,315 | 205,339,846 96.54% | 7,362,637 3.46% | 193,315 | Carried |
| 8 Issue shares - US Nasdaq initial public offering | Ordinary | 43,042,926 80.17% | 1,817,596 3.38% | 8,833,628 16.45% | 156,044,587 | 53,047,166 96.69% | 1,817,596 3.31% | 158,031,036 | Carried |
| 9 Approve issue of shares - US Nasdaq IPO to Apeiron | Ordinary | 198,966,229 94.94% | 1,718,566 0.82% | 8,891,158 4.24% | 162,784 | 207,313,722 97.45% | 5,419,292 2.55% | 162,784 | Carried |
| 10 Approve issue of shares - US Nasdaq IPO to BVF | Ordinary | 43,172,759 79.87% | 2,100,219 3.88% | 8,787,631 16.25% | 155,678,128 | 51,416,725 89.86% | 5,800,945 10.14% | 155,678,128 | Carried |
| 11 Proposed Employment Issue to Dr Errol De Souza | Ordinary | 197,178,256 94.34% | 3,031,734 1.45% | 8,801,465 4.21% | 727,282 | 203,415,607 96.80% | 6,732,460 3.20% | 2,747,731 | Carried |
| 12 Proposed IPO Issue to Dr Errol De Souza | Ordinary | 197,019,383 94.25% | 3,149,423 1.51% | 8,853,971 4.24% | 715,960 | 203,306,773 95.83% | 8,839,065 4.17% | 749,960 | Carried |
| 13 Approve termination benefits to Dr Errol De Souza | Ordinary | 192,603,997 92.15% | 7,577,353 3.63% | 8,812,391 4.22% | 378,298 | 200,836,256 94.67% | 11,314,546 5.33% | 378,298 | Carried |
| 14 Approval of Bionomics Limited Employee Equity Plan | Ordinary | 198,454,197 95.06% | 1,409,770 0.68% | 8,889,830 4.26% | 984,940 | 208,514,639 99.33% | 1,409,770 0.67% | 2,971,389 | Carried |
| 15 Approval of 10% Placement Facility | Special | 194,126,805 92.70% | 6,496,525 3.10% | 8,785,503 4.20% | 329,904 | 200,348,194 94.27% | 12,183,700 5.73% | 363,904 | Carried |

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.